|
Home | Issues | eMJA shop | My account | Classifieds | Contact | More... | Topics | Search |
→ Contents list for this issue
→ More articles on Neurology
→ Search PubMed for related articles
Click to Login
Hide the Login Box
→ Register for free access if you don't have an account
Introduction
—Prophylaxis in general
—What’s new?
—New drugs for prophylaxis
—Topiramate
—Candesartan
—Lisinopril
—Gabapentin
—Botulinum toxin
—Special circumstances
—Migraine with medication overuse
—Menstrual migraine
—Prominent or prolonged aura
—Impediments to new and emerging treatments in Australia
—Competing interests
—Author details
—References
There is a wide array of options for migraine prophylaxis; many of the available drugs are clearly proven to be effective and yet are underused in Australia.
“New” drugs which are gaining favour for migraine prophylaxis include topiramate, candesartan, gabapentin and botulinum toxin. The evidence for efficacy is excellent for topiramate and reasonably good but limited for candesartan and gabapentin. The use of botulinum toxin is controversial and has gained substantial popularity through anecdotal experience rather than convincing published evidence.
Transformed or chronic migraine with medication overuse is a particularly difficult problem. New strategies to aid in medication withdrawal are reviewed.
The approach to menstrual migraine and migraine with prominent aura may differ from that for typical migraine. Novel approaches are being explored for these problems.
Login or register for free access to the full article
|
|
Home | Issues | eMJA shop | My account | Classifieds | More... | Contact | Topics | Search |
©The Medical Journal of Australia 2008 www.mja.com.au PRINT ISSN: 0025-729X ONLINE ISSN: 1326-5377